JP2024515347A5 - - Google Patents

Info

Publication number
JP2024515347A5
JP2024515347A5 JP2023564511A JP2023564511A JP2024515347A5 JP 2024515347 A5 JP2024515347 A5 JP 2024515347A5 JP 2023564511 A JP2023564511 A JP 2023564511A JP 2023564511 A JP2023564511 A JP 2023564511A JP 2024515347 A5 JP2024515347 A5 JP 2024515347A5
Authority
JP
Japan
Prior art keywords
seq
variant
nucleotide sequence
sequence identity
promoter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564511A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515347A (ja
Filing date
Publication date
Priority claimed from GBGB2105686.6A external-priority patent/GB202105686D0/en
Application filed filed Critical
Publication of JP2024515347A publication Critical patent/JP2024515347A/ja
Publication of JP2024515347A5 publication Critical patent/JP2024515347A5/ja
Pending legal-status Critical Current

Links

JP2023564511A 2021-04-21 2022-04-21 キメラ抗原受容体(car)-t細胞 Pending JP2024515347A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2105686.6 2021-04-21
GBGB2105686.6A GB202105686D0 (en) 2021-04-21 2021-04-21 Chimeric antigen receptor (CAR)-T cells
PCT/GB2022/051004 WO2022223976A1 (en) 2021-04-21 2022-04-21 Chimeric antigen receptor (car)-t cells

Publications (2)

Publication Number Publication Date
JP2024515347A JP2024515347A (ja) 2024-04-09
JP2024515347A5 true JP2024515347A5 (https=) 2025-04-25

Family

ID=76377622

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564511A Pending JP2024515347A (ja) 2021-04-21 2022-04-21 キメラ抗原受容体(car)-t細胞

Country Status (9)

Country Link
US (1) US20240207313A1 (https=)
EP (1) EP4326760A1 (https=)
JP (1) JP2024515347A (https=)
KR (1) KR20240032719A (https=)
CN (1) CN117769566A (https=)
AU (1) AU2022262697A1 (https=)
CA (1) CA3215842A1 (https=)
GB (1) GB202105686D0 (https=)
WO (1) WO2022223976A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10245262B2 (en) 2014-04-01 2019-04-02 The University Of Queensland Immunological reagents and uses therefor
GB201506423D0 (en) * 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
JP2017529851A (ja) * 2014-09-26 2017-10-12 ベイラー カレッジ オブ メディスンBaylor College Of Medicine 養子免疫療法のためのグリピカン−3特異的キメラ抗原レセプター
JP7237449B2 (ja) * 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体(CARs)の構成およびその使用方法
CN109897114B (zh) * 2017-12-08 2022-08-02 亘喜生物科技(上海)有限公司 具有自杀基因开关的靶向cd47的工程化免疫细胞
GB201800298D0 (en) * 2018-01-09 2018-02-21 Autolus Ltd Method
EP4219688B1 (en) * 2018-12-19 2026-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors
WO2020156335A1 (zh) * 2019-01-29 2020-08-06 上海交通大学 一种嵌合抗原受体及其应用
US20230108300A1 (en) * 2020-01-29 2023-04-06 The Trustees Of The University Of Pennsylvania Compositions and methods of t cell receptor vb family member targeting for the treatment of t cell associated disease

Similar Documents

Publication Publication Date Title
CN112300269B (zh) Kras突变特异性t细胞受体筛选及抗肿瘤用途
JP7223822B2 (ja) 抗ヒトパピローマウイルス16 e6 t細胞受容体
JP7744479B2 (ja) 抗ヒトパピローマウイルス16 e7 t細胞受容体
JP6923714B2 (ja) Mhcクラスii拘束性mage−a3を認識するt細胞受容体
JP2024514355A5 (https=)
JP7684047B2 (ja) インターロイキン15融合タンパク質、およびその組成物ならびに治療方法
JP7385566B2 (ja) 突然変異rasに対するhlaクラスi拘束性t細胞受容体
AU2017258745B2 (en) Anti-KK-LC-1 T cell receptors
JP2022109953A5 (https=)
KR102557834B1 (ko) 신규의 세포 태그의 발현
KR102436129B1 (ko) T 세포 수용체 및 이의 용도
JP2020096630A5 (https=)
CN103483452B (zh) 双信号独立的嵌合抗原受体及其用途
JPH07501698A (ja) 二価特異性ヘテロ二量体
JP2023528112A (ja) G12d突然変異rasに対するhlaクラスi拘束性t細胞受容体
JP2025114614A (ja) G12r変異を有するrasに対するhlaクラスii拘束性t細胞受容体
JP2023527613A (ja) G12v変異を有するrasに対するhlaクラスii拘束性t細胞受容体
JP2024515347A5 (https=)
CN116284430A (zh) 靶向肿瘤的il15融合蛋白及其应用
EP4301470A1 (en) Combination therapies with sirp alpha-based chimeric proteins
KR102764613B1 (ko) NaPi2b 특이적 CAR-T를 포함하는 난소암 치료용 약학 조성물
WO2020257575A1 (en) T-cell receptor for treating fibrolamellar hepatocellular carcinoma
CN120882422A (zh) 一种用于治疗血液癌症的试剂盒
WO2025029881A1 (en) Combination therapy with a sirpa-based chimeric protein and azacitidine